

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-41 (Canceled).

42 (Currently Amended). A method of modulating the activity of a member of the polo serine/threonine kinase family in a subject, comprising administering a therapeutically effective amount effective to modulate the activity of the serine/threonine kinase in the subject of a peptide having the sequence of J-42 (SEQ ID NO.: 15), J-43 (SEQ ID NO.: 16), J-43.1 (SEQ ID NO.: 17), J-45 (SEQ ID NO.: 18) or J-46 (SEQ ID NO.: 19). comprising a peptide derivative of the HJ loop of a serine/threonine kinase, wherein:

a) said peptide has between about five and about twenty amino acids or amino acid analogs; and

b) said peptide modulates activity of the serine/threonine kinase.

43-50 (Canceled).